Fleury (FLRY3) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
14 Jul, 2026Executive summary
Gross revenue in Q1 2025 reached R$2.2 billion, up 6.5% year-over-year, with net profit rising 6.7% to R$179.3 million and EBITDA up 5.9% to R$547.6 million, maintaining a 27.2% margin.
ROIC improved to 16.9%, up 320 basis points from Q1 2023, marking the eighth consecutive quarter of growth.
Strong B2C and regional brand performance, with Fleury brand up 5.7%, other São Paulo brands up 9.6%, and regional brands up 14.1%.
Digital initiatives, especially digital scheduling, drove productivity gains and improved customer experience, now accounting for up to 45% of bookings in some brands.
Operational efficiency, disciplined capital allocation, and investments in technology supported financial resilience and value creation.
Financial highlights
Net revenue rose 5.8% to R$2.02 billion; gross profit increased 1.2% to R$572.1 million, with a gross margin of 28.4%.
Operating cash flow reached R$322.3 million, up 46.5% year-over-year; CapEx was R$66.9 million, with increased IT/digital investments.
Net debt/EBITDA at 1.0x, well below the 3.0x covenant limit; leverage remained low.
Financial result improved, with net financial expense down 6.3% to R$103.4 million.
Basic earnings per share: R$0.33, up from R$0.31 year-over-year.
Outlook and guidance
Management is confident in continued growth for 2025, with positive trends in B2C and healthy Lab-to-Lab performance excluding one-off toxicology effects.
Margin discipline and productivity gains expected from ongoing digital transformation and cost control.
Digital scheduling adoption is projected to rise further, supporting operational efficiency.
High payout ratio likely to be maintained, with strong cash generation supporting dividends.
The company maintained its previously disclosed projections for the year.
Latest events from Fleury
- Net income up 47.5% and EBITDA margin expands to 26.4% on strong B2C and B2B growth.FLRY3
Q2 202414 Jul 2026 - Gross revenue and net income rose, led by B2B, mobile, and successful integration efforts.FLRY3
Q3 202414 Jul 2026 - Revenue up 2.8% with stable EBITDA margin; net income fell on higher costs and depreciation.FLRY3
Q2 202514 Jul 2026 - Q3 2025 saw 11.5% revenue growth, stable margins, and continued expansion via acquisitions.FLRY3
Q3 202514 Jul 2026 - Double-digit revenue and EBITDA growth in 4Q25, led by B2C and strategic acquisitions.FLRY3
Q4 202514 Jul 2026 - Revenue up 10.1%, EBITDA up 10.7%, net income up 12.2%, led by B2C and regional growth.FLRY3
Q1 202614 Jul 2026 - Revenue up 19.5%, EBITDA up 19.6%, net income up 32%, with strong cash flow and ESG results.FLRY3
Q4 20242 Jul 2026 - Strong growth, expanded reach, and robust ESG drive leadership in Brazilian diagnostic medicine.FLRY3
Investor presentation16 Feb 2026